A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Remetinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions
  • Sponsors TetraLogic Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Apr 2014 Results have been reported in a TetraLogic Pharmaceuticals media release.
    • 13 Feb 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top